Cytrx Corp. has a market cap of $93.96 million; its shares were traded at around $0.861 with and P/S ratio of 9.89. CYTR is in the portfolios of Jim Simons of Renaissance Technologies LLC.
This is the annual revenues and earnings per share of CYTR over the last 10 years. For detailed 10-year financial data and charts, go to 10-Year Financials of CYTR.
Highlight of Business Operations:At September 30, 2010, we had cash and cash equivalents of approximately $10.2 million, marketable securities of approximately $20.6 million, held approximately 3.1 million shares of common stock of RXi with a market value of approximately $8.8 million based upon the closing price of the RXi common stock on that date. On March 26, 2010, we raised approximately $3.8 million from the sale of 675,000 RXi shares and on June 30, 2010, we sold 2.0 million shares of the RXi common stock for $5.0 million, net of costs. Management believes that our current cash on hand, together with our marketable securities and proceeds from possible future sales of RXi common stock, will be sufficient to fund our operations for the foreseeable future. The estimate is based, in part, upon our currently projected expenditures for the remainder of 2010 and the first nine months of 2011 of approximately $21.7 million, which includes approximately $3.4 million for our clinical programs for INNO-206, approximately $4.6 million for our clinical programs for bafetinib, approximately $4.6 million for our clinical program for tamibarotene, approximately $2.2 million for general operation of our clinical programs, and approximately $6.9 million for other general and administrative expenses. These projected expenditures are also based upon numerous other assumptions and subject to many uncertainties, and actual expenditures may be significantly different from these projections.
We realized a net loss in the quarter ended September 30, 2010 of $4.4 million as compared to a $3.9 million net income in the quarter ended September 30, 2009, or a difference of $8.3 million. We recognized no revenues in the quarter ended September 30, 2010 as compared to $7.0 million in the comparative 2009 quarter because all of the related ALSCRT revenue was completely recognized in 2009 as a result of the amendment of the ALSCRT arrangement discussed previously. Our research and development expenditures were approximately $0.4 million higher in the current quarter as compared to the quarter ended September 30, 2009, due to increased spending related to the ramp up of our oncology clinical trials. Our general and administrative expenditures were approximately $0.7 million lower in the current quarter as compared to the quarter ended September 30, 2009, due to a decrease in stock option expense.
In the nine-month period ended September 30, 2010, we received $10.8 million of cash from investing activities, compared to a usage of $26.7 million in the comparable 2009 period. In the current nine-month period, we received proceeds from the sale of 2.675 million RXi shares for a total of $8.9 million. We purchased marketable securities of $27.8 million in the nine-month period ended September 30, 2009 as compared to net proceeds of $2.2 million from the sale of marketable securities in the comparative 2009 period. We utilized $0.3 million for capital expenditures in the three-month period ended September 30, 2010 as compared to $0.1 million in the comparative 2009 period. We do not expect any significant capital spending during the next 12 months.
We recorded a net loss of approximately $4.4 million and net income of approximately $3.7 million for the three-month and nine-month periods ended September 30, 2010, respectively, as compared to a net income of approximately $3.9 million and a net loss of $2.3 million for the three-month and nine-month periods ended September 30, 2009, respectively. Our net income during the nine-month period of 2010 resulted from a gain on the sale of RXi of $8.9 million as well as a gain on the warrant derivative liability of $1.6 million.
As compensation to our consultants, and in connection with the acquisition of technology, we sometimes issue shares of common stock, stock options and warrants to purchase shares of common stock. For financial statement purposes, we value these shares of common stock, stock options, and warrants at the fair value of the common stock, stock options or warrants granted, or the services received, whichever is more reliably measurable. The value of the non-employee option grants are marked to market using the Black-Scholes option-pricing model and most of the compensation expense recognized or recovered during the period is adjusted accordingly. We recorded $53,000 and $141,000 of employee stock option expense both during the three-month and nine-month periods ended September 30, 2010, respectively, and $0.1 million and $0.5 million, respectively, for the same periods in 2009.
Employee stock option expense relates to options granted to recruit and retain directors, officers and other employees. We recorded approximately $0.2 million and $0.7 million of employee stock option expense in the three-month and nine-month periods ended September 30, 2010, as compared to $0.7 million and $1.3 million, respectively, for the same periods in 2009. We recorded $0 and $0.5 million of non-employee stock option expense in the three-month and nine-month periods ended September 30, 2010, as compared to $0.2 million and $0.4 million, respectively in the prior comparative periods.
Read the The complete Report